Serious immune‐related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review
- 15 August 2019
- journal article
- review article
- Published by Wiley in Head & Neck
- Vol. 41 (11) , 4036-4050
Abstract
Background: Immune checkpoint inhibitors confer significant clinical benefit by bolstering immune‐system activity, however, they also produce a spectrum of immune‐related adverse events (irAEs). Rapid recognition and timely treatment of these patients is essential for improved outcomes.Methods: We conducted a systematic review of English‐language articles in MEDLINE, EMBASE, Web of Science, PubMed, and Cochrane CENTRAL databases on patients with head and neck cancer treated with immune checkpoint inhibitors who developed treatment‐related adverse events.Results: Of 1715 unique citations, 11 studies met inclusion criteria. Eight patients with serious irAEs were reported from case reports and case series. Overall, 46 treatment‐related AEs were identified from the pooled 791 patients with at least 12 having potential relevance to irAEs. The most frequent AEs observed in patients receiving PD‐1 inhibitors involved the endocrine, cutaneous, and gastrointestinal systems.Conclusions: Characterizing irAEs in longitudinal studies is needed for developing strategies for their prompt recognition and management.Keywords
Funding Information
- National Institute of Dental and Craniofacial Research (R01 DE022891, 1R21DE026837)
- National Cancer Institute (P30 CA016672)
This publication has 56 references indexed in Scilit:
- Targeting IL-17 and TH17 cells in chronic inflammationNature Reviews Drug Discovery, 2012
- PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma CancerJournal of Immunotherapy, 2012
- Head and neck cancer—Part 1: Epidemiology, presentation, and preservationClinical Otolaryngology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyThe Lancet Oncology, 2010
- Advances in understanding of toxicities of treatment for head and neck cancerOral Oncology, 2009
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLOS Medicine, 2009
- CTLA4 blockade increases Th17 cells in patients with metastatic melanomaJournal of Translational Medicine, 2009
- Guidelines for submitting adverse event reports for publicationPharmacoepidemiology and Drug Safety, 2007
- Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanomaCancer, 2006